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Abstract: Background: This study aimed to evaluate the hospitalization rates for subarachnoid
hemorrhage (SAH) among renal transplant patients with adult polycystic kidney disease (ADPKD)
and its outcomes, when compared to non-ADPKD renal transplant patients. Methods: The 2005–2014
National Inpatient Sample databases were used to identify all hospitalized renal transplant patients.
The inpatient prevalence of SAH as a discharge diagnosis between ADPKD and non-ADPKD
renal transplant patients was compared. Among SAH patients, the in-hospital mortality, use of
aneurysm clipping, hospital length of stay, total hospitalization cost and charges between ADPKD
and non-ADPKD patients were compared, adjusting for potential confounders. Results: The
inpatient prevalence of SAH in ADPKD was 3.8/1000 admissions, compared to 0.9/1000 admissions in
non-ADPKD patients (p < 0.01). Of 833 renal transplant patients with a diagnosis of SAH, 30 had
ADPKD. Five (17%) ADPKD renal patients with SAH died in hospitals compared to 188 (23.4%)
non-ADPKD renal patients (p = 0.70). In adjusted analysis, there was no statistically significant
difference in mortality, use of aneurysm clipping, hospital length of stay, or total hospitalization costs
and charges between ADPKD and non-ADPKD patients with SAH. Conclusion: Renal transplant
patients with ADPKD had a 4-fold higher inpatient prevalence of SAH than those without ADPKD.
Further studies are needed to compare the incidence of overall admissions in ADPKD and non-ADPKD
patients. When renal transplant patients developed SAH, inpatient mortality rates were high regardless
of ADPKD status. The outcomes, as well as resource utilization, were comparable between the
two groups.
Keywords: autosomal dominant polycystic kidney disease; epidemiology; hospitalization; kidney
transplantation; subarachnoid hemorrhage
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1. Introduction
Subarachnoid hemorrhage (SAH) is a major clinical problem worldwide, associated with a
poor prognosis, long-term morbidity, and extremely high mortality [1–3]. In the United States, over
30,000 cases of SAH occur annually [4,5]. Although global SAH has decreased each year from
1960 through 2017 [6], approximately 30% to 50% of patients who developed SAH died at 60 days.
Furthermore, over 30% of survivors subsequently suffered neurologic deficits post-SAH [1–4,7–9].
Major causes of SAH include ruptured intracranial aneurysm, cerebral arteriovenous malformation,
and traumatic brain injury [6,10].
Among patients with autosomal dominant polycystic kidney disease (ADPKD), a disorder that
affects the kidneys and other organs caused by mutations in PKD1 and PKD2, a wide spectrum of
vascular abnormalities have been described including intracranial aneurysms (and dolichoectasias),
thoracic aorta and cervicocephalic artery dissections, and coronary artery aneurysms [11,12]. Compared
to the general population, the prevalence of intracranial aneurysms in ADPKD patients is approximately
five times higher and is estimated at 4% to 22.5% [13–19]. Among ADPKD patients with a family
history of SAH/intracranial aneurysms, the frequency is three to five times higher than the general
population [12]. Thus, screening is recommended for intracranial aneurysms among ADPKD patients
with (1) family or past medical history of intracranial aneurysm presence or rupture; (2) symptoms
suggesting intracranial aneurysm; (3) occupations in which loss of consciousness may be fatal;
(4) upcoming major elective surgery; and (5) patient subjective concern for possible intracranial
aneurysm presence [20–22].
Despite the recommendation for intracranial aneurysm screening prior to major elective surgery,
such screening for ADPKD patients is not consistently performed among all transplant centers in
the USA during pre-transplant assessment for renal transplantation [23,24]. In addition, previously
published studies on the increased risk of SAH after renal transplantation in patients with ADPKD
have not yielded relevant information, or have been underpowered [25–31].
Thus, we conducted this study using a nationwide inpatient USA database to evaluate the
hospitalization rates for SAH among renal transplant patients with ADPKD and its outcomes, when
compared to non-ADPKD renal transplant patients.
2. Methods
2.1. Data Source
The 2005–2014 National Inpatient Sample (NIS) databases were used to conduct this retrospective
cohort study. The NIS is the largest inpatient all-payer database that is publicly available in the US.
This database was developed by the Agency for Healthcare Research and Quality (AHRQ) as part of
its Healthcare Cost and Utilization Project (HCUP). The dataset for the studied years contains more
than 78 million hospitalizations, which in itself is a 20% stratified sample of over 4000 non-federal
acute care hospitals in 44 states of the United States, and is representative of 95% of hospitalizations
nationwide. This dataset included codes for principal diagnosis, secondary diagnoses, and codes for
procedures performed during the hospitalization.
2.2. Study Population
Initially, renal transplant patients were identified using the International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) codes of v42.0. The ADPKD status in this cohort
was identified using the ICD-9-CM code 753.13. The associated diagnosis of SAH was identified using
the ICD-9-CM code 430. Patients undergoing elective hospital admission or patients undergoing renal
transplantation during the same admission were excluded from the analysis.
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2.3. Variable Definition
Patient characteristics included age, gender, ethnicity, median income in patients’ zip code, family
history of stroke, and insurance type. Hospital characteristics included hospital region, teaching
status, number of hospital beds, urban location, and weekend admission. The Healthcare Cost and
Utilization Project (HCUP) divides the US into four census regions based on geographical location:
Northeast, Midwest, South and West. The vital status at the end of hospitalization, length of hospital
stay (LOS), and total hospitalization charges were abstracted from the database. To account for
patient comorbidities, the Deyo adaptation of the Charlson Comorbidity Index was used, which was
appropriate for the large database analysis [32].
2.4. Outcomes
The outcome for primary analysis was to determine the inpatient prevalence of SAH as a discharge
diagnosis in renal transplant patients with ADPKD, compared to renal transplant patients without
ADPKD. The outcomes for secondary analysis were to compare in-hospital mortality, the use of
aneurysm clipping, length of hospital stay, and expenditures between ADPKD and non-ADPKD
patients with SAH. Expenditures included total hospitalization charges and hospitalization costs.
Total hospitalization charges represented the amount of financial resources that each hospital billed
for providing its service for each patient, whereas hospitalization costs represented the amount of
money spent by each hospital in providing the patient care. Hospitalization costs were calculated by
multiplying the cost-to-charge ratios for the respective hospitals with the total hospitalization charges.
Cost-to-charge ratios were provided by the Healthcare Cost and Utilization Project (HCUP) for each
hospitalization in the database in order to enable this calculation. Since this study used datasets for
10 different calendar years, costs and charges were adjusted for inflation using the consumer price
index and converting them to 2014 $USD equivalents.
2.5. Statistical Analysis
Discharge-level weights on the HCUP nationwide databases were used to estimate the total
number of renal transplant patients that had an associated diagnosis of SAH. Descriptive statistics
were used to identify the patient characteristics. Fisher’s exact test was used to compare proportions.
Students’ t-test was used to compare means. A hybrid multivariate logistic regression model was
built by first conducting a univariate regression analysis on variables that were identified from other
studies as being relevant to the outcome. If these variables impacted the outcome in any direction with
a p-value of <0.01, they were included in the multivariate logistic regression model. In multivariate
logistic regression, odds ratios and means were adjusted for age, gender, insurance type, family
history of stroke, the median income in patients’ zip code, hospital region, urban location, number of
hospital beds and teaching status. All statistical analyses were performed using STATA, Version 13
(StataCorp LP, College Station, TX, USA).
3. Results
3.1. Inpatient Prevalence of SAH as a Discharge Diagnosis
Out of 382,516,561 patients admitted to hospitals during the study period, 918,478 were identified
as having had a history of renal transplant. ADPKD patients who underwent renal transplant had
higher inpatient prevalence of SAH as a discharge diagnosis than non-ADPKD renal transplant patients
(3.8 vs. 0.9 cases per 1000 discharges; p < 0.01).
3.2. Patient and Hospital Characteristics in SAH Patients
In total, 833 patients had an associated diagnosis of SAH. These included 30 ADPKD renal
transplant patients and 803 non-ADPKD renal transplant patients. The ADPKD renal transplant
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patients were older, had higher comorbidity burden, and were more likely to be admitted to teaching
hospitals than non-ADPKD renal patients. There was no significant difference in terms of weekend
admission, the median income in patients’ zip code, insurance type, hospital region, urban location,
and number of hospital beds between the two cohorts (Table 1).
Table 1. Patient and hospital characteristics.
Patient Characteristics Non-ADPKD (n = 803) ADPKD (n = 30) p-Value
Mean age (years) 53.4 58.9 <0.01
Female gender (%) 491 (61.2%) 18 (59.1%) 0.7
Ethnicity
Caucasian 522 (65%) 21 (70%)
African American 112 (14%) 3 (10%) 0.02
Hispanic 145 (18%) 5 (18%)
Other 24 (3%) 1 (2%)
Weekend admission 193 (24%) 5 (18%) 0.17
Income in zip code
$1–37,999 217 (27%) 6 (21%)
$38,000–47,999 208 (26%) 8 (28%) 0.36
$48,000–63,999 193 (24%) 7 (22%)
>$64,000 185 (23%) 9 (29%)
Insurance
Medicare 313 (39%) 9 (29%)
Medicaid 104 (13%) 4 (13%) 0.28
Private 321 (40%) 14 (48%)
Self-Pay 64 (8%) 3 (10%)
Charlson score
0 0 (0%) 0 (0%)
1–2 586 (73%) 13 (42%) <0.01
>3 214 (27%) 17 (58%)
Hospital Region
Northeast 145 (18%) 6 (19%)
Midwest 177 (22%) 7 (23%) 0.15
South 297 (37%) 8 (25%)
West 185 (23%) 10 (33%)
Urban Location 779 (97%) 29 (98%) 0.39
Hospital Number of Beds
Small 48 (6%) 2 (6%)
Medium 145 (18%) 4 (14%) 0.64
Large 610 (76%) 24 (80%)
Hospital Teaching Status 602 (75%) 26 (88%) <0.01
ADPKD, adult polycystic kidney disease.
3.3. Mortality
A total of 5 (17%) ADPKD renal transplant patients with SAH died in hospitals compared to 188
(23.4%) non-ADPKD renal transplant patients (p = 0.70). Similarly, in adjusted analysis, there was no
difference in in-hospital mortality between the two groups, with an adjusted odds ratio (aOR) of 0.87
(95% confidence interval (CI) 0.12–6.23; p = 0.89) (Table 2).
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Table 2. Outcomes and procedures of ADPKD and non-ADPKD patients with SAH.
Outcome Adjusted OR 95% CI p-Value
Mortality 0.87 (0.12–6.23) 0.89
Procedure Adjusted OR 95% CI p-Value
Aneurysm clipping 2.02 0.28–14.81 0.49
3.4. Use of Aneurysm Clipping
Ten (33.0%) ADPKD renal transplant patients with SAH underwent aneurysm clipping, compared
to 137 (17.1%) non-ADPKD renal transplant patients (p = 0.32). On adjusted analysis, the use of
aneurysm clipping in ADPKD renal transplant patients was not significantly higher than non-ADPKD
renal transplant patients (aOR: 2.02; 95% CI 0.28–14.81; p = 0.49) (Table 2).
3.5. Hospital Length of Stay
The mean LOS in ADPKD renal transplant patients with SAH was 9.8 days, compared to 8.9 days
in the non-ADPKD renal transplant SAH patients. Although the mean additional LOS in ADPKD renal
transplant patients with SAH was 3.0 days shorter than non-ADPKD renal transplant patients with
SAH, this was not statistically significant (95% CI: −10.1–4.1, p = 0.41) on adjusted analysis (Table 3).
Table 3. Hospital length of stay and expenditure differences between ADPKD and non-ADPKD patients
with SAH.
Additional Expenditures Mean Difference 95% CI p-Value
Hospital length of stay (days) −3.0 −10.1–4.1 0.41
Total hospitalization cost −$1086 −$22,548–$20,376 0.92
Total hospitalization charge −$14,944 −$73,293–$43,404 0.62
3.6. Total Hospitalization Costs and Charges
The mean hospital cost for ADPKD renal transplant patients with SAH was $ 30,519, while
the mean hospital cost for non-ADPKD renal transplant patients with SAH was $ 33,526 (p = 0.04).
Although the ADPKD renal transplant patients with SAH had a mean hospital cost $ 1086 lower
than the non-ADPKD renal transplant patients, the difference was not statistically significant (95% CI:
−22,548–20,376, p = 0.92) on adjusted analysis (Table 3).
The mean total hospitalization charge for ADPKD renal transplant patients with SAH was $ 85,682,
while the mean total hospitalization charges for non-ADPKD renal transplant patients with SAH was $
112,514. Although ADPKD renal transplant patients with SAH had a mean hospitalization charge $
14,944 lower than the non-ADPKD renal transplant patients, this was not statistically significant (95%
CI: −73,293–43,404, p = 0.62) on adjusted analysis (Table 3).
4. Discussion
In this study utilizing the USA Nationwide Inpatient Sample database, we demonstrated that
renal transplant patients with ADPKD had a 4-fold higher inpatient prevalence of SAH than those
without ADPKD. When renal transplant patients developed SAH, the inpatient mortality rate was
high (around 20 to 30%), regardless of ADPKD status. In addition, the use of aneurysm clipping for
SAH and hospital LOS were comparable among renal transplant patients with and without ADPKD.
In the previous analysis using USA Renal Data System registry data, Lentine et al. reported a
decreased risk of SAH in renal transplant patients when compared to end-stage renal disease (ESRD)
patients on the transplant waiting list [33]. Additionally, among ESRD patients on dialysis, it has been
shown that ADPKD is associated with an increased risk of SAH [34,35]. Despite an overall reduction
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in SAH risk after renal transplantation [33], our study demonstrates a higher relative frequency of
SAH among ADPKD patients compared to those without ADPKD and aims to raise awareness that
SAH remains an important concern in the post-transplantation population.
The risk of intracranial aneurysms among ADPKD patients increased with age [36,37] and its
prevalence is substantially increased after 45 years of age, especially among ADPKD Caucasian
patients [38]. The average age of patients with ADPKD and ESRD is greater than 45 years [34,35,38].
However, intracranial aneurysm screening during pre-transplant evaluation for renal transplantation
was a requirement for some but not all transplant centers in the USA, despite recommendation for
intracranial aneurysm screening prior to major elective surgery [23,24]. Furthermore, a very recent
study by Flahault et al. including 495 ADPKD patients suggested that systematic screening was
cost-effective and provided a gain of 0.68 quality-adjusted life years compared to targeted screening in
only those with a familial history of intracranial aneurysms [21]. The investigators concluded that
intracranial aneurysm screening could be proposed to all ADPKD patients regardless of family history
of stroke [21].
In our study involving renal transplanted patients, after adjusting for potential confounders
including family history of stroke, the relative frequency of SAH among ADPKD patients remained
significantly higher compared to those without ADPKD. This may suggest potential development of
SAH in renal transplant patients with ADPKD, regardless of family history of stroke. When patients
develop SAH, the mortality rate is high regardless of renal transplant status [27,33,39–41]. In our study,
nearly 25% of renal transplant patients with SAH died during hospital admission. After adjusting for
potential confounders, we found no differences in in-hospital mortality, rate of aneurysm clipping,
hospital LOS, hospital costs and total hospitalization charges among ADPKD and non-ADPKD renal
transplant patients with SAH.
Several limitations of this study must be acknowledged. Firstly, although the utilization of the NIS
database enables an assessment of inpatient relative frequency and burden of SAH in renal transplant
patients in the USA, potential inaccuracies in ICD-9-CM coding are significant limitations to our study.
Secondly, the data relating to types of mutation among ADPKD patients were limited in this study.
Since patients with PKD2-associated ADPKD usually develop ESRD at an older age compared to
renal-transplanted ADPKD patients (mean age: 79.7 vs. 58.9 years) [22,42,43], it is likely that our
study represents the outcomes of SAH among renal transplant patients with PKD1-associated ADPKD.
Thirdly, this is an analysis of an inpatient USA database and, thus, it does not consider the broader USA
outpatient renal transplant population nor the renal transplant population in other countries. Because
of the nature of the NIS database, our study included only inpatient renal transplant patients and
might be subject to selection bias. Without knowing the total number of all ADPKD and non-ADPKD
renal transplant patients, the overall admission rates for any reasons cannot be calculated. Fourthly,
although the findings of our study highlight the burden of SAH in ADPKD renal transplant patients, it
cannot be concluded that screening all ADPKD patients prior to renal transplantation is cost-effective.
Nevertheless, physicians should take into account the risk of SAH among ADPKD renal transplant
patients. Furthermore, the practice of intracranial aneurysm screening in ADPKD patients might vary
between hospitals. However, information regarding the practice of intracranial aneurysm screening
was not available in our study. Lastly, given the administrative nature of the dataset, it was not
possible to investigate the effects of medication, such as immunosuppressants, on economic burden
and mortality among ADPKD and non-ADPKD renal transplant patients with SAH.
5. Conclusions
In conclusion, in this study using the USA Nationwide Inpatient Sample database, we demonstrate
higher inpatient relative frequency of SAH among ADPKD renal transplant patients when compared
with non-ADPKD renal transplant patients. In-hospital mortality due to SAH among renal transplant
patients was high, regardless of ADPKD status. The use of aneurysm clipping for SAH and hospital
length of stay were comparable between ADPKD renal transplant patients and those without ADPKD.
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